Analyst Consensus ?
ConsensusBuy49 ratings
Bullish3571.4%
Neutral1428.6%
Bearish00.0%
FN2 Earnings Intelligence
Regeneron Pharmaceuticals, Inc. analyst ratings
Regeneron Pharmaceuticals, Inc. (REGN) analyst consensus, price targets, and firm-level rating history from FN2 Research.
Analyst 52W Price Targets
$816.1Current
$584Low
$853.69Average
$1,292High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Buy | Buy | Maintain | Oct 21, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Oct 19, 2026 |
| UBS | Buy | Neutral | Upgrade | Oct 15, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Oct 8, 2026 |
| Truist Securities | Buy | Buy | Maintain | Oct 7, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 7, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 6, 2026 |
| Jefferies | Buy | Buy | Maintain | Oct 1, 2026 |
| Argus Research | Buy | Hold | Upgrade | Oct 1, 2026 |
| HSBC | Buy | Buy | Maintain | Sep 10, 2026 |
| Leerink Partners | Market Perform | Market Perform | Maintain | Aug 17, 2026 |
| Guggenheim | Buy | Buy | Maintain | Aug 3, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 3, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 31, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Benchmark | Buy | Hold | Upgrade | Jul 7, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | May 19, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | May 18, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 30, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Apr 8, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Feb 2, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jan 22, 2026 |
| B of A Securities | Buy | Underperform | Upgrade | Jan 7, 2026 |
| Scotiabank | Sector Perform | Sector Perform | Maintain | Nov 24, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Apr 30, 2025 |
| Baird | Neutral | Neutral | Maintain | Apr 30, 2025 |
| Raymond James | Outperform | Market Perform | Upgrade | Nov 3, 2023 |
| EF Hutton | Buy | Buy | Maintain | May 1, 2023 |
| SVB Leerink | Outperform | Market Perform | Upgrade | Mar 27, 2023 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Jan 30, 2023 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Nov 5, 2021 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 23, 2021 |
| SunTrust Robinson Humphrey | Buy | Hold | Upgrade | Jul 9, 2020 |
| CFRA | Hold | Hold | Maintain | May 27, 2020 |
| Argus | Hold | Buy | Downgrade | Jun 18, 2019 |
| Leerink Swann | Outperform | Outperform | Maintain | Feb 9, 2018 |
| BTIG Research | Neutral | Buy | Downgrade | Feb 9, 2018 |
| BTIG | Neutral | Buy | Downgrade | Feb 9, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Dec 13, 2017 |
| PiperJaffray | Overweight | Neutral | Upgrade | Feb 13, 2017 |
| Chardan Capital | Neutral | Sell | Upgrade | Dec 12, 2016 |
| Roth Capital | Buy | Buy | Maintain | Apr 4, 2016 |
| Gabelli & Co. | Buy | Buy | Maintain | Mar 15, 2016 |
| Brean Capital | Buy | Buy | Maintain | Feb 10, 2016 |
| Bank of America | Buy | Buy | Maintain | Nov 21, 2014 |
| Argus Capital | Buy | Buy | Maintain | Jul 21, 2014 |
| Lazard | Buy | Buy | Maintain | Sep 13, 2013 |
| JMP Securities | Perform | Market Perform | Maintain | Mar 28, 2013 |
| Bank oferica | Buy | Buy | Maintain | May 29, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $816.1. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Piper Sandler | Analyst unavailable | $865 | $790.74 | +6.0% | Oct 19, 2026 |
| UBS | Analyst unavailable | $978 | $778.36 | +19.8% | Oct 14, 2026 |
| RBC Capital | Brian Abrahams | $810 | $730.08 | -0.7% | Oct 8, 2026 |
| Raymond James | Chris Raymond | $911 | $742.12 | +11.6% | Oct 8, 2026 |
| Truist Financial | Analyst unavailable | $780 | $747.51 | -4.4% | Oct 7, 2026 |
| Morgan Stanley | Analyst unavailable | $779 | $743.6 | -4.5% | Oct 7, 2026 |
| Jefferies | Analyst unavailable | $930 | $741.16 | +14.0% | Oct 1, 2026 |
| BMO Capital | Evan David Seigerman | $920 | $741.41 | +12.7% | Oct 1, 2026 |
| Argus Research | Analyst unavailable | $850 | $758.27 | +4.2% | Oct 1, 2026 |
| HSBC | Rajesh Kumar | $920 | $807.65 | +12.7% | Sep 10, 2026 |
| Leerink Partners | David Risinger | $824 | $803.48 | +1.0% | Aug 17, 2026 |
| Bernstein | Jeffrey Walch | $756 | $799.46 | -7.4% | Aug 14, 2026 |
| Guggenheim | Analyst unavailable | $1,030 | $763.51 | +26.2% | Aug 3, 2026 |
| RBC Capital | Analyst unavailable | $737 | $739.5 | -9.7% | Jul 31, 2026 |
| Morgan Stanley | Analyst unavailable | $758 | $738.82 | -7.1% | Jul 31, 2026 |
| Cantor Fitzgerald | Carter Gould | $795 | $742.59 | -2.6% | Jul 31, 2026 |
| Robert W. Baird | Analyst unavailable | $761 | $738.34 | -6.8% | Jul 31, 2026 |
| Wells Fargo | Analyst unavailable | $750 | $738.34 | -8.1% | Jul 31, 2026 |
| Guggenheim | Yatin Suneja | $1,000 | $675.72 | +22.5% | Jul 21, 2026 |
| Piper Sandler | Biren Amin | $854 | $662.88 | +4.6% | Jul 9, 2026 |
| Morgan Stanley | Terence Flynn | $730 | $676.23 | -10.6% | Jul 8, 2026 |
| Truist Financial | Analyst unavailable | $769 | $670.54 | -5.8% | Jul 7, 2026 |
| HSBC | Analyst unavailable | $800 | $643 | -2.0% | Jul 6, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $750 | $654.27 | -8.1% | Jul 6, 2026 |
| Canaccord Genuity | John Newman | $875 | $629.68 | +7.2% | May 19, 2026 |
| Wolfe Research | Alexandria Hammond | $860 | $629.36 | +5.4% | May 18, 2026 |
| Evercore ISI | Analyst unavailable | $825 | $619.84 | +1.1% | May 18, 2026 |
| RBC Capital | Analyst unavailable | $707 | $619.62 | -13.4% | May 18, 2026 |
| Truist Financial | Analyst unavailable | $778 | $619.95 | -4.7% | May 18, 2026 |
| BMO Capital | Analyst unavailable | $730 | $698.25 | -10.6% | May 18, 2026 |
| Piper Sandler | Analyst unavailable | $855 | $698.25 | +4.8% | May 18, 2026 |
| Leerink Partners | Market Perform | $641 | $698.25 | -21.5% | May 18, 2026 |
| Guggenheim | Yatin Suneja | $995 | $707.06 | +21.9% | May 1, 2026 |
| Morgan Stanley | Terence Flynn | $788 | $703.18 | -3.4% | Apr 30, 2026 |
| Truist Financial | Analyst unavailable | $796 | $692.75 | -2.5% | Apr 30, 2026 |
| Barclays | Analyst unavailable | $917 | $686.36 | +12.4% | Apr 30, 2026 |
| Raymond James | Chris Raymond | $910 | $746.58 | +11.5% | Apr 22, 2026 |
| Morgan Stanley | Analyst unavailable | $796 | $746.15 | -2.5% | Apr 10, 2026 |
| Bernstein | Analyst unavailable | $921 | $775.53 | +12.9% | Apr 8, 2026 |
| Truist Financial | Greg Renza | $818 | $770.32 | +0.2% | Mar 9, 2026 |
| Barclays | Eliana Merle | $923 | $764.93 | +13.1% | Mar 6, 2026 |
| RBC Capital | Brian Abrahams | $765 | $784.06 | -6.3% | Mar 2, 2026 |
| Guggenheim | Analyst unavailable | $975 | $785.51 | +19.5% | Feb 9, 2026 |
| Cantor Fitzgerald | Carter Gould | $800 | $757.59 | -2.0% | Feb 2, 2026 |
| Robert W. Baird | Brian Skorney | $742 | $755.34 | -9.1% | Feb 2, 2026 |
| Oppenheimer | Analyst unavailable | $865 | $741.45 | +6.0% | Feb 2, 2026 |
| Tudor Pickering | William Pickering | $925 | $753.13 | +13.3% | Feb 2, 2026 |
| Morgan Stanley | Terence Flynn | $769 | $741.45 | -5.8% | Feb 1, 2026 |
| Raymond James | Analyst unavailable | $870 | $741.45 | +6.6% | Jan 30, 2026 |
| Tudor Pickering | William Pickering | $916 | $762.1 | +12.2% | Jan 27, 2026 |
| RBC Capital | Brian Abrahams | $745 | $769.05 | -8.7% | Jan 27, 2026 |
| Bernstein | Analyst unavailable | $916 | $762.65 | +12.2% | Jan 27, 2026 |
| Evercore ISI | Analyst unavailable | $875 | $761.56 | +7.2% | Jan 22, 2026 |
| Goldman Sachs | Analyst unavailable | $914 | $812.27 | +12.0% | Jan 8, 2026 |
| Leerink Partners | Andrew Berens | $873 | $746.36 | +7.0% | Dec 17, 2025 |
| Morgan Stanley | Terence Flynn | $768 | $741.52 | -5.9% | Dec 12, 2025 |
| HSBC | Analyst unavailable | $985 | $692.58 | +20.7% | Dec 10, 2025 |
| BMO Capital | Evan Seigerman | $850 | $723.67 | +4.2% | Dec 4, 2025 |
| Canaccord Genuity | Analyst unavailable | $1,057 | $723.67 | +29.5% | Dec 4, 2025 |
| Truist Financial | Analyst unavailable | $798 | $766.5 | -2.2% | Nov 24, 2025 |
| Scotiabank | Analyst unavailable | $770 | $769.23 | -5.6% | Nov 24, 2025 |
| HSBC | Analyst unavailable | $890 | $755.9 | +9.1% | Nov 24, 2025 |
| Wells Fargo | Mohit Bansal | $700 | $702.75 | -14.2% | Nov 20, 2025 |
| RBC Capital | Analyst unavailable | $708 | $653.01 | -13.2% | Oct 29, 2025 |
| Cantor Fitzgerald | Carter Gould | $740 | $657 | -9.3% | Oct 29, 2025 |
| BMO Capital | Evan Seigerman | $725 | $654.48 | -11.2% | Oct 29, 2025 |
| Wells Fargo | Analyst unavailable | $615 | $654.48 | -24.6% | Oct 29, 2025 |
| Robert W. Baird | Analyst unavailable | $637 | $645.93 | -21.9% | Oct 29, 2025 |
| Bernstein | Analyst unavailable | $818 | $654.42 | +0.2% | Oct 29, 2025 |
| Guggenheim | Analyst unavailable | $865 | $654.48 | +6.0% | Oct 29, 2025 |
| Robert W. Baird | Brian Skorney | $630 | $654.48 | -22.8% | Oct 29, 2025 |
| Raymond James | Christopher Raymond | $723 | $654.48 | -11.4% | Oct 28, 2025 |
| Morgan Stanley | Analyst unavailable | $767 | $654.48 | -6.0% | Oct 28, 2025 |
| Morgan Stanley | Analyst unavailable | $756 | $568.81 | -7.4% | Oct 10, 2025 |
| Raymond James | Christopher Raymond | $673 | $577.9 | -17.5% | Sep 2, 2025 |
| BMO Capital | Analyst unavailable | $640 | $571.54 | -21.6% | Aug 4, 2025 |
| Wells Fargo | Mohit Bansal | $580 | $563.43 | -28.9% | Aug 1, 2025 |
| UBS | Trung Huynh | $584 | $559.76 | -28.4% | Jul 11, 2025 |
| Morgan Stanley | Terence Flynn | $754 | $560.28 | -7.6% | Jul 10, 2025 |
| Morgan Stanley | Terence Flynn | $755 | $490.81 | -7.5% | Jun 2, 2025 |
| Cantor Fitzgerald | Carter Gould | $695 | $585.49 | -14.8% | Apr 22, 2025 |
| Canaccord Genuity | John Newman | $850 | $585.49 | +4.2% | Apr 22, 2025 |
| BMO Capital | Analyst unavailable | $903 | $666.87 | +10.6% | Mar 14, 2025 |
| BMO Capital | Evan David Seigerman | $1,190 | $843.6 | +45.8% | Nov 1, 2024 |
| Piper Sandler | Christopher Raymond | $1,195 | $843.6 | +46.4% | Nov 1, 2024 |
| Leerink Partners | Andrew Berens | $880 | $843.6 | +7.8% | Nov 1, 2024 |
| Evercore ISI | Cory Kasimov | $1,170 | $838.2 | +43.4% | Oct 31, 2024 |
| Evercore ISI | Cory Kasimov | $1,175 | $941.39 | +44.0% | Oct 24, 2024 |
| Wells Fargo | Mohit Bansal | $1,050 | $962.34 | +28.7% | Oct 23, 2024 |
| Truist Financial | Thomas Klee | $1,200 | $1,091.98 | +47.0% | Sep 24, 2024 |
| Leerink Partners | David Risinger | $1,077 | $1,091.98 | +32.0% | Sep 24, 2024 |
| Robert W. Baird | Brian Skorney | $940 | $1,091.98 | +15.2% | Sep 24, 2024 |
| Goldman Sachs | Salveen Richter | $1,292 | $1,091.98 | +58.3% | Sep 24, 2024 |
| BMO Capital | Evan David Seigerman | $1,300 | $1,159.94 | +59.3% | Sep 12, 2024 |
| RBC Capital | Brian Abrahams | $1,282 | $1,139.41 | +57.1% | Sep 9, 2024 |
| Raymond James | Christopher Raymond | $1,242 | $1,187.66 | +52.2% | Aug 23, 2024 |
| Bank of America Securities | Geoff Meacham | $805 | $1,077.48 | -1.4% | Aug 2, 2024 |
| RBC Capital | Brian Abrahams | $1,240 | $1,093.14 | +51.9% | Aug 2, 2024 |
| Raymond James | Christopher Raymond | $1,166 | $1,063.6 | +42.9% | Jul 19, 2024 |
| Guggenheim | Yatin Suneja | $1,180 | $1,085.62 | +44.6% | Jul 18, 2024 |
| UBS | Trung Huynh | $1,250 | $1,092.31 | +53.2% | Jul 12, 2024 |
| Morgan Stanley | Terence Flynn | $1,182 | $1,071.12 | +44.8% | Jul 11, 2024 |
| Argus Research | Jasper Hellweg | $1,170 | $1,063.89 | +43.4% | Jun 25, 2024 |
| RBC Capital | Brian Abrahams | $1,299 | $1,022.03 | +59.2% | Jun 13, 2024 |
| RBC Capital | Brian Abrahams | $1,229 | $1,010.54 | +50.6% | Jun 12, 2024 |
| RBC Capital | Brian Abrahams | $1,200 | $998.64 | +47.0% | Jun 4, 2024 |
| BMO Capital | Evan David Seigerman | $1,082 | $992.47 | +32.6% | Jun 3, 2024 |
| Raymond James | Christopher Raymond | $1,000 | $982.29 | +22.5% | May 20, 2024 |
| Evercore ISI | Cory Kasimov | $1,150 | $976.96 | +40.9% | May 13, 2024 |
| RBC Capital | Brian Abrahams | $1,185 | $937.61 | +45.2% | May 3, 2024 |
| Jefferies | Akash Tewari | $1,060 | $911.78 | +29.9% | Apr 12, 2024 |
| RBC Capital | Brian Abrahams | $1,189 | $921.34 | +45.7% | Apr 11, 2024 |
| Morgan Stanley | Matthew Harrison | $1,115 | $965.47 | +36.6% | Mar 13, 2024 |
| BMO Capital | Brian Abrahams | $1,076 | $934.06 | +31.8% | Jan 12, 2024 |
| RBC Capital | Brian Abrahams | $1,076 | $933.2 | +31.8% | Jan 12, 2024 |
| Leerink Partners | Andrew Berens | $976 | $820 | +19.6% | Mar 27, 2023 |
| Jefferies | Akash Tewari | $925 | $819.68 | +13.3% | Mar 24, 2023 |
| EF Hutton | Analyst unavailable | $853 | $769.94 | +4.5% | Feb 8, 2023 |
| RBC Capital | Analyst unavailable | $787 | $786.94 | -3.6% | Feb 6, 2023 |
| Morgan Stanley | Analyst unavailable | $883 | $783.13 | +8.2% | Feb 6, 2023 |
| Leerink Partners | Analyst unavailable | $834 | $783.13 | +2.2% | Feb 6, 2023 |
| Guggenheim | Analyst unavailable | $915 | $707.63 | +12.1% | Nov 11, 2022 |
| Goldman Sachs | Analyst unavailable | $970 | $726.93 | +18.9% | Oct 3, 2022 |
| Canaccord Genuity | Analyst unavailable | $750 | $710.21 | -8.1% | Sep 16, 2022 |
| Piper Sandler | Analyst unavailable | $775 | $701.15 | -5.0% | Sep 13, 2022 |
| Wells Fargo | Analyst unavailable | $800 | $718.82 | -2.0% | Sep 12, 2022 |
| Barclays | Analyst unavailable | $815 | $708.85 | -0.1% | Sep 9, 2022 |
| Morgan Stanley | Matthew Harrison | $851 | $708.85 | +4.3% | Sep 9, 2022 |
| Jefferies | Akash Tewari | $675 | $708.85 | -17.3% | Sep 8, 2022 |
| Morgan Stanley | Matthew Harrison | $625 | $628.71 | -23.4% | Aug 15, 2022 |
| BMO Capital | Analyst unavailable | $788 | $614.96 | -3.4% | Aug 4, 2022 |
| Morgan Stanley | Analyst unavailable | $619 | $604.3 | -24.2% | Jul 15, 2022 |
| RBC Capital | Kennen MacKay | $638 | $597.62 | -21.8% | Jun 29, 2022 |
| Wells Fargo | Mohit Bansal | $735 | $571.81 | -9.9% | Jun 11, 2022 |
| Morgan Stanley | Analyst unavailable | $610 | $626.94 | -25.3% | Jun 3, 2022 |
| Argus Research | Analyst unavailable | $760 | $683.02 | -6.9% | May 31, 2022 |
| Leerink Partners | Geoffrey Porges | $738 | $680.22 | -9.6% | May 23, 2022 |
| Credit Suisse | Lorenzo Biasio | $725 | $681.91 | -11.2% | May 23, 2022 |
| Morgan Stanley | Analyst unavailable | $620 | $638.13 | -24.0% | May 5, 2022 |
| Barclays | Carter Gould | $745 | $733.02 | -8.7% | Apr 16, 2022 |
| BMO Capital | Evan David Seigerman | $780 | $638.41 | -4.4% | Feb 13, 2022 |
| Barclays | Carter Gould | $700 | $622.36 | -14.2% | Feb 7, 2022 |
| RBC Capital | Kennen MacKay | $679 | $622.96 | -16.8% | Feb 4, 2022 |
| Cowen & Co. | Tyler Van Buren | $640 | $622.96 | -21.6% | Feb 4, 2022 |
| J.P. Morgan | Cory Kasimov | $604 | $622.96 | -26.0% | Feb 4, 2022 |
| Evercore ISI | Joshua Schimmer | $680 | $622.85 | -16.7% | Feb 2, 2022 |
| Morgan Stanley | Matthew Harrison | $585 | $611.22 | -28.3% | Jan 18, 2022 |
| Bernstein | Aaron Gal | $660 | $627.1 | -19.1% | Jan 3, 2022 |
| Goldman Sachs | Salveen Richter | $824 | $625 | +1.0% | Dec 6, 2021 |
| Cantor Fitzgerald | Alethia Young | $760 | $622.2 | -6.9% | Nov 10, 2021 |
| UBS | Esther Rajavelu | $763 | $646.11 | -6.5% | Sep 9, 2021 |
| Argus Research | Jasper Hellweg | $590 | $528.75 | -27.7% | Jun 14, 2021 |
| Canaccord Genuity | John Newman | $700 | $506.72 | -14.2% | May 21, 2021 |
Track every rating change on REGN the moment it posts. Free to start.
Start freeGet the REGN recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.